

Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K/A

CALLISTO PHARMACEUTICALS INC

Form 8-K/A

May 13, 2004

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2003

Callisto Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	333-63474	65-110840
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	IRS Employer Identification No.)

420 Lexington Avenue, Suite 2500  
New York, New York 10170  
(Address of principal executive offices)

Registrant's telephone number, including area code: (212) 297-0010

(Former name or former address, if changed since last report)

Explanatory Note

This Current Report on Form 8-K/A is being filed to amend the Registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 15, 2003 to replace the financial statements filed under Item 7(a) and (b) in their entirety with the attached financial statements.

The balance sheets of Callisto Pharmaceuticals, Inc. ("Callisto") as of December 31, 2002 and 2001 and the related statements of operations, stockholders' equity and cash flows for the years ended December 31, 2002 and 2001 and for the period from June 5, 1996 (inception) to December 31, 2002 have been restated to reflect

## Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K/A

the following:

- (i) The purchase of Webtronics for \$400,000 in 2002 was recorded as an investment on the previously issued balance sheet as of December 31, 2002. In these restated financial statements Callisto has recorded the purchase price as a cost of becoming a public company, however because there was no capital raised at the time, the amount was charged to general and administrative expense in 2002.
- (ii) Patent costs were previously capitalized and amortized over the life of the patent. Callisto has never had any commercial biopharmaceutical products, and does not expect to have such for several years, if at all. The amount incorrectly capitalized, net of accumulated amortization, on the previously issued balance sheet as of December 31, 2002 was \$461,961. On a restated basis, Callisto has recorded additional research and development expense of \$19,733, \$106,632 and \$461,961, respectively, for the twelve months ended December 31, 2002 and 2001 and for the period from June 5, 1996 (inception) to December 31, 2002.
- (iii) Stock-based compensation from June 5, 1996 (inception) to December 31, 2002 had not been recorded. A review of stock and option records back to inception, together with a re-assessment of the facts and circumstances at the time, indicated a need to record stock-based compensation expense. Stock-based compensation expense for the years ended December 31, 2002 and 2001 and for the period from June 5, 1996 (inception) to December 31, 2002 was \$332, \$22,155 and \$4,784,556, respectively.

### Item 7 - Financial Statements and Exhibits.

Included in the Form 8-K filed by the Registrant on May 15, 2003 were the financial statements of Synergy Pharmaceuticals Inc. ("Synergy") as it was originally determined to constitute an acquisition of a business. Subsequently it was determined that this transaction constituted an acquisition of assets which does not require the filing of the financial statements of Synergy. With respect to pro forma financial statements that are required for a significant acquisition of assets, because the terms of the acquisition, the consideration paid, the accounting treatment and the pro forma effects of such have been disclosed in Footnote # 4 to the financial statements of the Registrant as of December 31, 2003 and for the years ended December 31, 2003 and 2002 as filed in Form 10-KSB with the SEC on April 14, 2004, the Registrant has determined that it is not meaningful or necessary to include any pro forma financial information in this amended Form 8-K.

- (a) Index to Financial Statements

Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K/A

	Page
Report of Independent Certified Public Accountants	F-2
Balance Sheets as of December 31, 2002 and 2001	F-3
Statements of Operations for the years ended December 31, 2002 and 2001, and for the period from June 5, 1996 (inception) to December 31, 2002	F-4
Statements of Changes in Stockholders' Equity for the period from June 5, 1996 (inception) to December 31, 2002	F-5
Statements of Cash Flows for the years ended December 31, 2002 and 2001, and for the period from June 5, 1996 (inception) to December 31, 2002	F-6
Notes to financial statements	F-7

F-1

Report of Independent Certified Public Accountants

Board of Directors  
Callisto Pharmaceuticals, Inc.  
New York, New York

We have audited the accompanying balance sheets of Callisto Pharmaceuticals, Inc. (a development stage company) (the "Company") as of December 31, 2002 and 2001, and the related statements of operations, stockholders' equity, and cash flows for the years then ended and for the period from June 5, 1996 (inception) to December 31, 2002. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Callisto Pharmaceuticals, Inc. as of December 31, 2002 and 2001, and the results of its operations and its cash flows for the years then ended and for the period from June 5, 1996 (inception) to December 31, 2002, in conformity with accounting principles generally accepted in the United States.

These financial statements, which were previously audited by other auditors, have been restated as described in Note 10.

/s/ BDO Seidman, LLP  
-----

Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K/A

New York, New York  
April 8, 2004

F-2

CALLISTO PHARMACEUTICALS, INC.  
(A Development Stage Company)  
BALANCE SHEETS as of December 31,  
(Restated)

ASSETS

	2002	2001
Current assets:		
Cash and cash equivalents	\$ 2,223,462	\$ 3,627,479
Prepaid expenses	28,456	19,660
	-----	-----
	2,251,918	3,647,139
Equipment, net	19,781	4,530
	-----	-----
	\$ 2,271,699	\$ 3,651,669
	=====	=====

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:		
Accounts payable and accrued expenses	\$ 442,834	\$ 138,171
Stockholders' equity:		
Preferred stock \$.0001 par value 20,000,000 shares authorized, 4,235,299 issued and outstanding	423	423
Common stock, \$.0001 par value, authorized 60,000,000 shares, 13,083,695 outstanding at December 31, 2002 and 2001	1,307	1,307
Additional paid-in-capital	14,538,618	14,538,618
Unamortized deferred stock based compensation	---	(332)
Deficit accumulated during the development stage	(12,711,483)	(11,026,518)
	-----	-----
	1,828,865	3,513,498
	-----	-----
	\$ 2,271,699	\$ 3,651,669
	=====	=====

The accompanying notes are an integral part of these financial statements.

F-3

CALLISTO PHARMACEUTICALS, INC.  
(A Development Stage Company)  
STATEMENTS OF OPERATIONS

Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K/A

(Restated)

	For the year ended December 31,		For Period June (Incep Dece
	2002	2001	
Revenues	\$ ---	\$ ---	\$
Costs and Expenses:			
Research and development	491,430	653,402	3,
General and administrative	1,227,699	938,893	4,
Stock-based compensation	332	22,155	4,
Loss from operations	(1,719,461)	(1,614,450)	(13,
Interest income	34,496	182,404	
Net loss	\$ (1,684,965)	\$ (1,432,046)	\$ (12,
Weighted average shares outstanding:			
Basic and diluted	17,318,994	17,318,994	
Net loss per common share: Basic and diluted	\$ (0.10)	\$ (0.08)	

The accompanying notes are an integral part of these financial statements.

F-4

CALLISTO PHARMACEUTICALS, INC.  
(A Development Stage Company)  
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY  
(Restated)

	Preferred Shares	Preferred Stock Par Value	Common Shares	Common Stock Par Value	Additional Paid-in Capital	Unamort Defer Stoc Base Compens
Balance at inception, June 5, 1996	---	\$---	---	\$ ---	\$ ---	\$
Net loss for the period	---	---	---	---	---	
Issuance of founder shares	---	---	2,642,500	264	528	

Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K/A

Common stock issued	---	---	1,356,194	136	272	
Common stock issued via private placement	---	---	1,366,667	137	1,024,863	
Balance, December 31, 1996	---	---	5,365,361	537	1,025,663	
Net loss for the year	---	---				
Common stock issued via private placement	---	---	1,442,667	144	1,081,855	
Balance, December 31, 1997	---	---	6,808,028	681	2,107,518	
Net loss for the year	---	---				
Amortization of stock based compensation	---	---			52,778	
Common stock issued via private placement	---	---	1,416,667	142	1,062,358	
Common stock issued for services	---	---	788,889	79	591,588	
Common stock repurchased and cancelled	---	---	(836,792)	(84)	(96,916)	
Balance, December 31, 1998	---	---	8,176,791	818	3,717,326	
Net loss for the year	---	---				
Deferred Compensation - stock options	---	---			9,946	(9)
Amortization of stock based compensation	---	---				3
Common stock issued for services	---	---			3,168,832	
Common stock issued via private placement	---	---	346,667	34	259,966	
Balance, December 31, 1999	---	---	8,523,458	852	7,156,070	(6)
Net loss for the year	---	---				
Amortization of stock based compensation	---	---				4
Common stock issued	---	---	4,560,237	455	250,889	
Other	---	---			432	

CALLISTO PHARMACEUTICALS, INC.  
(A Development Stage Company)  
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Continued)

Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K/A

(Restated)

	Preferred Shares	Preferred Stock Par Value	Common Shares	Common Stock Par Value	Additional Paid-in Capital	Unamort Defer Stock Base Compens
Preferred shares issued	3,485,299	348	---	---	5,986,302	
Preferred stock issued for services	750,000	75	---	---	1,124,925	
Balance, December 31, 2000	4,235,299	423	13,083,695	1,307	14,518,618	(2)
Net loss for the year	---	---	---	---	---	
Deferred Compensation - stock options	---	---	---	---	20,000	(20)
Amortization of stock based compensation	---	---	---	---	---	22
Balance, December 31, 2001	4,235,299	423	13,083,695	1,307	14,538,618	
Net loss for the year	---	---	---	---	---	
Amortization of stock based compensation	---	---	---	---	---	
Balance, December 31, 2002	4,235,299	\$423	13,083,695	\$1,307	\$14,538,618	\$

The accompanying notes are an integral part of these financial statements.

F-5

CALLISTO PHARMACEUTICALS, INC.  
 (A Development Stage Company)  
 STATEMENTS OF CASH FLOWS  
 (Restated)

Year ended December 31,	Per Jun (Ince Dece 2
2002	2001
-----	-----

## Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K/A

Cash flows from operating activities:			
Net loss	\$ (1,684,965)	\$ (1,432,046)	\$ (12,711,483)
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation and amortization	6,778	2,118	
Stock based compensation expense	332	22,155	4,000
Changes in operating assets and liabilities:			
Prepaid expenses	(8,796)	(19,854)	
Accounts payable and accrued expenses	304,663	107,173	
Total adjustments	302,977	111,592	5,000
Net cash used in operating activities	(1,381,988)	(1,320,454)	(7,711,483)
Cash flows from investing activities:			
Acquisition of equipment	(22,029)	-	
Net cash used in investing activities	(22,029)	-	
Cash flows from financing activities:			
Net proceeds from issuance stock, net of repurchases	-	-	9,000
Net cash provided by financing activities	-	-	9,000
Net increase (decrease) in cash and cash equivalents	(1,404,017)	(1,320,454)	2,000
Cash and cash equivalents at beginning of year	3,627,479	4,947,933	
Cash and cash equivalents at end of year	\$ 2,223,462	\$ 3,627,479	\$ 2,947,933
Supplementary disclosure of cash flows information:			
Cash paid for taxes	\$ 13,487	\$ 11,863	\$ 11,863

The accompanying notes are an integral part of these financial statements.

F-6

CALLISTO PHARMACEUTICALS, INC.  
(A Development Stage Company)  
NOTES TO FINANCIAL STATEMENTS

1. Business overview:

Callisto Pharmaceuticals, Inc. ("Callisto" or "Old Callisto") is a development stage biopharmaceutical company, whose primary focus is on biopharmaceutical product development. See footnote 4 for a complete description of a recent business combination and basis of presentation. Since inception in June of 1996 our efforts have been principally devoted to research and development, securing and protecting our patents and raising capital. From inception through December 31, 2002, Callisto has sustained cumulative net losses of \$12,711,483. Callisto's losses have resulted primarily from expenditures incurred in connection with research and development activities, application and filing for regulatory approval of our proposed products, stock based compensation expense, patent filing and maintenance expenses, outside accounting and legal services and regulatory, scientific and financial consulting fees. From inception through December 31, 2002 Callisto has not generated any revenue from operations, expects to incur additional losses to perform further research and development



## Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K/A

activities and does not currently have any commercial biopharmaceutical products, and does not expect to have such for several years, if at all.

Callisto's product development efforts are thus in their early stages and Callisto cannot make estimates of the costs or the time it will take to complete. The risk of completion of any program is high because of the many uncertainties involved in bringing new drugs to market including the long duration of clinical testing, the specific performance of proposed products under stringent clinical trial protocols, the extended regulatory approval and review cycles, the nature and timing of costs and competing technologies being developed by organizations with significantly greater resources.

### 2. Basis of presentation:

The accompanying financial statements of Callisto have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP").

F-7

### 3. Summary of significant accounting policies

Use of Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents - Cash and cash equivalents consist of short term, highly liquid investments, with original maturities of less than three months when purchased and are stated at cost.

Fair value of financial instruments - Callisto's financial instruments consist of cash and accounts payable. These financial instruments are stated at their respective carrying values which are equivalent to fair value due to their short term nature.

Business concentrations and credit risks - All of Callisto's cash and cash equivalents as of December 31, 2002 and 2001 are on deposit with one major money center financial institution. Deposits at any point in time may exceed federally insured limits.

Accounting for stock based compensation - Callisto has adopted Statement of Financial Accounting Standard ("SFAS") No. 123, "Accounting for Stock-Based Compensation". As provided for by SFAS 123, Callisto has also elected to continue to account for its stock-based compensation programs according to the provisions of Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees ("APB 25")." Accordingly, compensation expense has been recognized to the extent of employee or director services rendered based on the intrinsic value of stock options granted under the plans.

Recent accounting pronouncement - In December 2002, the Financial Accounting Standards Board issued SFAS No. 148, "Accounting for Stock-Based Compensation-Transition and Disclosure, an amendment of FASB Statement No. 123", to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, this statement amends the disclosure requirements of SFAS No. 123 to require prominent disclosures in both annual (see below) and interim financial statements about the method of accounting for stock-based employee compensation

## Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K/A

and the effect of the method used on reported results.

F-8

Had compensation cost for stock options granted to employee and directors been determined based upon the fair value at the grant date for awards, consistent with the methodology prescribed under SFAS 123, Callisto's net loss would have been as follows:

	Years ended December 31,	
	2002	2001
Net loss, as reported	\$ (1,684,965)	\$ (1,432,046)
Add: Stock-based employee compensation expense recorded under APB No. 25 intrinsic method	---	20,000
Deduct: Stock-based employee compensation expense determined under fair value based method for all employee awards	---	(198,114)
Pro forma net loss	\$ (1,684,965)	\$ (1,610,160)
Net loss per share:		
Basic and diluted - as reported	\$ (0.10)	(0.08)
Basic and diluted - pro forma	\$ (0.10)	\$ (0.09)

The fair value of the options granted to employees during 2001 ranged from \$0.00 to \$0.50 on the date of grant using the Black-Scholes methodology. The following weighted average assumptions were used for determining fair value in 2002 and 2001: no dividend yield, expected volatility of 0%, risk free interest rate of 4.50% and expected lives of 7 to 10 years.

Net Loss per Share - Basic and diluted net loss per share is presented in conformity with SFAS No. 128, "Earnings per Share", for all periods presented. In accordance with SFAS No. 128, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Diluted weighted-average shares are the same as basic weighted-average shares since the inclusion of issuable shares pursuant to the exercise of stock options, would have been antidilutive.

F-9

Research and development - Callisto does not currently have any commercial biopharmaceutical products, and does not expect to have such for several years,

## Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K/A

if at all and therefore research and development costs are expensed as incurred. These include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, application and filing for regulatory approval of our proposed products, patent filing and maintenance expenses, regulatory and scientific consulting fees as well as contract research and royalty payments to outside research suppliers, facilities and universities. In addition 100% of the salary of Callisto's Chief Executive Officer was also included in research and development expense during the twelve months ended December 31, 2002 and 2001 due to his extensive involvement with Callisto's product development efforts.

Income taxes - Income taxes are accounted for under the asset and liability method prescribed by Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes." Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or the entire deferred tax asset will not be realized.

#### 4. Merger and consolidation:

In March 2002, Old Callisto purchased 99.7% of the outstanding common shares of Webtronics, Inc., ("Webtronics") a public company for \$400,000. Webtronics was incorporated in Florida on February 2, 2001 and had limited operations during the year ended December 31, 2002. The purchase price of Webtronics was treated as a cost of becoming a public company, however because there was no capital raised at the time, the amount was charged to general and administrative expense during the year ended December 31, 2002.

On April 30, 2003, pursuant to an Agreement and Plan of Merger dated March 10, 2003, as amended April 4, 2003, Synergy Acquisition Corp., a wholly-owned subsidiary of Webtronics merged into Synergy Pharmaceuticals Inc. ("Synergy") and Callisto Acquisition Corp., a wholly-owned subsidiary of Webtronics merged into Old Callisto (collectively, the "Merger"). As a result of the Merger, Old Callisto and Synergy became wholly-owned subsidiaries of Webtronics. In connection with the Merger Webtronics issued 17,318,994 shares of its common stock in exchange for outstanding Old Callisto common stock and an additional 4,395,684 shares in exchange for outstanding Synergy common stock. Subsequently, 171,818 shares of common stock issued to former Synergy shareholders were returned to Callisto under the terms of certain indemnification agreements. The Merger was accounted for as a recapitalization of Old Callisto by an exchange of Webtronics common stock for the net assets of Old Callisto consisting primarily of cash and fixed assets. Old Callisto then changed its name to Callisto Research Labs, LLC and Webtronics changed its name to Callisto Pharmaceuticals, Inc. and changed its state of incorporation from Florida to Delaware. Callisto Pharmaceuticals, Inc. (formerly Webtronics) remains the continuing legal entity and registrant for Securities and Exchange Commission reporting purposes.

F-10

The total consideration related to the Merger was allocated in full to the Synergy research and development projects which had not yet reached technological feasibility and having no alternative use was charged to purchased in-process research and development expense during the year ended December 31, 2003.

#### 5. Equipment:

## Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K/A

Equipment consists of laboratory, testing and computer equipment, stated at cost, with useful lives ranging from 2-4 years, depreciated on a straight line basis. Depreciation expense for the years ended December 31, 2002 and 2001 and from June 5, 1996 (inception) to December 31, 2002 was \$6,778, \$2,118 and \$10,394, respectively.

	December 31,	
	2002	2001
Equipment	\$ 30,175	\$ 8,146
Less - Accumulated depreciation	(10,394)	(3,616)
Equipment, net	\$ 19,781	\$ 4,530
	=====	=====

### 6. Stock option plan:

In 1996, Callisto adopted an incentive and non-qualified stock option plan (the "Plan") for employees, consultants and outside directors to purchase up to 2,000,000 shares of common stock. The Plan was amended in December 2002 to increase the number of shares authorized under the Plan to 10,000,000. The option term for options granted under the Plan is ten years from date of grant and there were 8,152,941 option shares available for future grants as of December 31, 2002.

Callisto recognizes deferred stock-based compensation expense for the intrinsic value of stock options granted to employees and directors. Deferred stock-based compensation is amortized to stock-based compensation expense over the vesting period of the stock option. During the twelve months ended December 31, 2002, 2001 and for the period from June 5, 1996 (inception) to December 31, 2002 Callisto recognized \$332, \$22,155 and \$4,784,556, respectively, as stock-based compensation expense related to issuance of stock and stock options. At December 31, 2002 and 2001, unamortized deferred stock-based compensation was \$0 and \$332, respectively.

F-11

The following represent options outstanding for the years since June 5, 1996 (inception) through December 31, 2002.

	Number of Shares	Exercise Price Per Share
Balance, June 5, 1996 (inception)	0	\$0.00
1996: Granted	66,668	\$0.75
Balance, December 31, 1996	66,668	\$0.75
1997: Granted	166,668	\$0.75

Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K/A

Balance, December 31, 1997	233,336	\$0.75
1998: Granted	264,169	\$0.75
Balance, December 31, 1998	497,505	\$0.75
1999: Granted	633,334	\$0.75 - \$4.90
Balance, December 31, 1999	1,130,839	\$0.75 - \$4.90
2000: Granted	815,666	\$2.85 - \$6.75
Forfeitures	(15,000)	\$ 0.75
Balance, December 31, 2000	1,931,505	\$0.75 - \$6.75
2001: Granted	730,000	\$1.25 - \$6.50
Balance, December 31, 2001	2,661,505	\$0.75 - \$6.75
2002: Granted	330,000	\$4.50 - \$6.50
Balance, December 31, 2002	2,991,505	\$0.75 - \$6.75

Included in the balance at December 31, 2002 were 1,144,446 non-Plan options, all exercisable. Options are exercisable as follows at December 31, 2002:

Exercise Price	Options Outstanding			Number of Shares
	Number of Shares	Weighted Average Remaining Life	Weighted Average Exercise Price	
\$0.75	615,839	6.1 years	\$0.75	615,839
\$1.25	400,000	8.1 years	\$1.25	400,000
\$1.95 - \$2.85	1,129,000	7.3 years	\$2.57	999,000
\$4.90 - \$6.75	846,666	8.4 years	\$5.53	306,666
All options:				
\$0.75 - \$6.75	2,991,505	7.3 years	\$2.86	2,321,505

F-12

7. Income taxes:

At December 31, 2002, Callisto had available Federal net operating tax loss carry forwards of approximately \$6,000,000 expiring through 2021 to offset future taxable income. The net deferred tax asset has been fully offset by a valuation allowance due to uncertainties regarding realization of benefits from these future tax deductions. As a result of the change in control provisions of Internal Revenue Code Section 382, a significant portion of these net operating loss carry forwards may be subject to limitation on future utilization.

## Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K/A

### 8. Commitments and contingencies:

On July 25, 2001, Callisto entered into a license agreement to research, develop, sell and commercially exploit certain Rockefeller University licensed patents covering peptides and antibodies useful in treating toxic shock syndrome and septic shock. Callisto will pay Rockefeller a \$7,500 annual maintenance fee until the first commercial sale of the product. Callisto will pay royalties of 2% and 0.75% of net sales of product as defined in the agreement and will pay Rockefeller 15% of any sublicense fee paid by sublicensees. The agreement will terminate upon the later of (a) expiration of the last to expire or become abandoned patent right or (b) 20 years after the effective date of the agreement. During the twelve months ended December 31, 2002 and 2001, Callisto paid Rockefeller University \$7,500 and \$13,918, respectively.

On April 11, 2001, Callisto entered into a license agreement with Dartmouth College to research, develop, manufacture and sell certain Dartmouth patent rights covering a method to enhance antibiotics against Staphylococcus and other bacteria. Callisto was obligated to pay to Dartmouth a minimum annual license fee of \$10,000 for 2002; \$15,000 for 2003 and \$25,000 per annum for 2004 and thereafter. During the twelve months ended December 31, 2002 and 2001 Callisto paid Dartmouth \$265,261 and \$174,135, respectively, under this agreement. In August 2003, Callisto and Dartmouth entered into a settlement and general release agreement, which terminated this license. Pursuant to the settlement and general release agreement, Callisto paid \$42,868 to Dartmouth.

On July 7, 1998 Callisto entered into a Patent License Agreement with the United States Public Health Service ("PHS"), under which Callisto had an exclusive license to make, use, sell, lease, import and export and to otherwise commercially exploit certain licensed patents covering a diagnostic method for detecting obsessive compulsive disorder. Callisto paid an initial license issue royalty fee in the amount of \$50,000 in 1998 and during the twelve months ended December 31, 2002 and 2001 Callisto paid royalty fees of \$10,000 and \$99,754, respectively, under this agreement and minimum annual royalties fees of \$10,000 in each year through December 31, 2002. Callisto terminated this agreement by mutual consent in January 2004.

During the years ended December 31, 2002 and 2001 and for the period from June 5, 1996 (inception) to December 31, 2002, Callisto had a month-to-month lease arrangement and total rent expense was \$51,856, \$30,659 and \$119,822, respectively.

F-13

### 9. Stockholders' equity:

During 2000, the Board of Directors approved an increase in the authorized common shares from 35,000,000 shares to 60,000,000 shares and a one-for-three reverse split of the common stock. All share and per share information has been adjusted to reflect the stock split as if it had occurred at the beginning of the earliest period presented. In May 2003, as part of the Merger, the authorized common shares were increased to 75,000,000 shares and the authorized preferred shares were increased to 20,000,000 shares.

During 2000, Callisto sold 2,252,441 shares of Series A convertible preferred stock at \$1.70 per share and 1,232,858 shares of Series B convertible preferred stock at \$1.75 per share. In addition the Board of Directors authorized the issuance of 750,000 shares of Series C convertible preferred stock at \$0.10 per share to an executive officer of Callisto. The net proceeds from the sale of these 4,235,299 shares of convertible preferred stock totaled \$6,061,650. The holders of the convertible preferred stock had equal voting rights with the

## Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K/A

common stockholders, had certain liquidation preferences and were convertible at any time into shares of common stock at a ratio of one share of common stock for each share of convertible preferred stock at the election of the holder. Callisto recorded compensation expenses of approximately \$1,050,000 related to the shares sold to the executive officer. During the second quarter of 2003 all of the convertible preferred stockholders converted their shares of preferred stock to common stock in connection with the Merger.

During 2000, Callisto also sold 4,526,903 shares of common stock at a purchase price of \$0.05 per share to certain officers and directors of the company for services performed in the year 1999. Based on the most recent private placement of common stock during the fourth quarter of 1999, the value of these shares was determined to be \$0.70 per share and Callisto recorded \$3,168,832 as stock based compensation expense for the twelve months ended December 31, 1999.

During 1998, as part of a settlement agreement between the founding partners of CSO Ventures, Inc. and Callisto, one of the founders of CSO sold 836,792 shares of common stock back to Callisto at a price of approximately \$0.12 per share, for \$97,000. Concurrently Callisto entered into a stock purchase agreement with a private investor to sell him 766,667 shares of common stock at a price of \$92,000 or \$0.12 per share. The fair value of the common stock issued was determined to be \$0.75 per share based on the most recent sale price of common stock paid by investors in Callisto's private placements and Callisto recorded \$483,000 of stock based compensation expense.

F-14

During the period from December 1996 to December 1999, Callisto completed the following private placements of its common stock:

	Shares -----	Price per share -----	Gross proceeds -----
December 1996	1,366,667	\$0.75	\$1,025,000
December 1997	1,442,667	\$0.75	1,081,999
October 1998	1,416,667	\$0.75	1,062,500
January 1999	146,667	\$0.75	110,000
December 1999	200,000	\$0.75	150,000
	-----		-----
Total	4,572,668 =====		\$3,429,499 =====

### 10. Restatement:

The balance sheets as of December 31, 2002 and 2001 and the related statements of operations, stockholders' equity and cash flows for the years ended December 31, 2002 and 2001 and for the period from June 5, 1996 (inception) to December 31, 2002 have been restated to reflect the following:

The purchase of Webtronics for \$400,000 in 2002 was recorded as an investment on the previously issued balance sheet as of December 31, 2002. This has been recorded as general and administrative expense in 2002.

Patent costs were previously capitalized and amortized over the life of the patent. Callisto does not currently have any commercial biopharmaceutical products, and does not expect to have such for several years, if at all. The amount incorrectly capitalized, net of accumulated amortization, as of December 31, 2002 was \$461,961. On a restated basis, Callisto has recorded research and development expense of \$19,733, \$106,632 and \$461,961, respectively, for the

## Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K/A

twelve months ended December 31, 2002 and 2001 and for the period from June 5, 1996 (inception) to December 31, 2002.

Stock-based compensation from June 5, 1996 (inception) to December 31, 2002 had not been recorded. A review of stock and option records back to inception, together with a re-assessment of the facts and circumstances at the time, indicated a need to record stock-based compensation expense. Stock-based compensation expense for the years ended December 31, 2002 and 2001 and for the period from June 5, 1996 (inception) to December 31, 2002 was \$332, \$22,155 and \$4,784,556, respectively.

### 11. Subsequent event:

In April 2003, Callisto settled legal fees totaling approximately \$352,000, accrued as of December 31, 2002, for approximately \$100,000. The balance was reversed into general and administrative expense in the second quarter of 2003.

F-15

### Item 7 - Financial Statements and Exhibits (Continued)

(b) Pro Forma Financial Information - None

(c) Exhibits

Exhibit No.	Description
2.1	Agreement and Plan of Merger dated March 10, 2003*
2.2	Amendment to Agreement and Plan of Merger dated April 4, 2003*
4.1	Callisto Stock Option Plan*
99.1	Descriptive Memorandum of Callisto Pharmaceuticals, Inc.*

\* Previously filed.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereto duly authorized.

Dated: May 13, 2004

CALLISTO PHARMACEUTICALS, INC.

By: /s/ Gary S. Jacob  
-----  
Gary S. Jacob  
Chief Executive Officer